According to the actual WHO, reporting double/triple CNG is not a mandatory component for the diagnosis of a DLBCL, NOS, but given the recent reports on clinical outcome, we suggest that double/triple CNG should be reported similar to overexpression of C-MYC and BCL2 [13–15]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.